Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

61.28USD
19 Jan 2018
Change (% chg)

$0.15 (+0.25%)
Prev Close
$61.13
Open
$61.35
Day's High
$61.45
Day's Low
$60.64
Volume
4,492,095
Avg. Vol
3,700,507
52-wk High
$66.80
52-wk Low
$53.63

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $167,132.30
Shares Outstanding(Mil.): 2,727.35
Dividend: 0.48
Yield (%): 3.13

Financials

  Industry Sector
P/E (TTM): -- 33.09 17.86
EPS (TTM): -- -- --
ROI: -- 15.01 33.11
ROE: -- 16.57 17.05

BRIEF-Merck says First-Time Data For Keytruda In Patients With Previously Treated Advanced Hepatocellular Carcinoma To Be Presented At 2018 ASCO GI Symposium

* FIRST-TIME DATA FOR MERCK'S KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC) TO BE PRESENTED AT 2018 ASCO GI SYMPOSIUM

Jan 19 2018

Positive Keytruda lung cancer data sends Merck shares up 6 percent

Positive lung cancer results for Merck & Co Inc's blockbuster drug Keytruda assuaged investor concerns about delays in testing and the withdrawal of an application for European use of the drug, sending the drugmaker's shares up more than 6 percent.

Jan 16 2018

UPDATE 3-Positive Keytruda lung cancer data sends Merck shares up 6 pct

* Results cement Merck's lead in first-line lung cancer market

Jan 16 2018

BRIEF-Merck & Co Says Keytruda Phase 3 Keynote-189 Trial Met Its Dual Primary Endpoints

* MERCK'S KEYTRUDA(R) (PEMBROLIZUMAB) SIGNIFICANTLY IMPROVED OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL AS FIRST-LINE TREATMENT IN COMBINATION WITH PEMETREXED AND PLATINUM CHEMOTHERAPY FOR PATIENTS WITH METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER (KEYNOTE-189)

Jan 16 2018

Merck's Keytruda succeeds in key lung cancer trial

Jan 16 Merck & Co Inc said on Tuesday that a key late-stage study testing its blockbuster drug Keytruda as a treatment for a type of lung cancer was successful.

Jan 16 2018

BRIEF-Eisai, Merck Receive Breakthrough Therapy Designation From FDA For Lenvima, Keytruda

* EISAI AND MERCK RECEIVE BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR LENVIMA® (LENVATINIB MESYLATE) AND KEYTRUDA® (PEMBROLIZUMAB) AS COMBINATION THERAPY FOR ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA

Jan 09 2018

BRIEF-Merck's Keytruda Significantly Improved Recurrence-Free Survival Compared To Placebo As Adjuvant Therapy

* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) SIGNIFICANTLY IMPROVED RECURRENCE-FREE SURVIVAL COMPARED TO PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH STAGE 3 RESECTED HIGH-RISK MELANOMA (EORTC1325/KEYNOTE-054)

Jan 08 2018

BRIEF-FDA Accepts New Drug Applications For Merck's Doravirine

* FDA ACCEPTS NEW DRUG APPLICATIONS FOR MERCK’S DORAVIRINE, THE COMPANY’S INVESTIGATIONAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI), FOR TREATMENT OF HIV-1 INFECTION

Jan 08 2018

BRIEF-Merck’s Keytruda Approved In Japan For Use In The Treatment Of Patients With Urothelial Carcinoma

* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) APPROVED IN JAPAN FOR USE IN THE TREATMENT OF PATIENTS WITH UROTHELIAL CARCINOMA THAT IS UNRESECTABLE WITH RADICAL SURGERY WHO HAVE PROGRESSED FOLLOWING CANCER CHEMOTHERAPY

Jan 02 2018

BRIEF-FDA Approves SGLT2 Inhibitor Steglatro And Fixed-Dose Combination Steglujan For Adults With Type 2 Diabetes

* FDA APPROVES SGLT2 INHIBITOR STEGLATRO™ (ERTUGLIFLOZIN) AND FIXED-DOSE COMBINATION STEGLUJAN™ (ERTUGLIFLOZIN AND SITAGLIPTIN) FOR ADULTS WITH TYPE 2 DIABETES

Dec 22 2017

Competitors

Earnings vs. Estimates